期刊
CELL REPORTS
卷 13, 期 11, 页码 2480-2490出版社
CELL PRESS
DOI: 10.1016/j.celrep.2015.11.040
关键词
-
类别
资金
- CRUK [RG69667]
- Dutch Cancer Foundation (KWF)
- Cancer Research UK [16942] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0611-10154] Funding Source: researchfish
The transforming growth factor beta (TGF-beta) signaling pathway exerts opposing effects on cancer cells, acting as either a tumor promoter or a tumor suppressor. Here, we show that these opposing effects are a result of the synergy between SMAD3, a downstream effector of TGF-beta signaling, and the distinct epigenomes of breast-tumor-initiating cells (BTICs). These effects of TGF-beta are associated with distinct gene expression programs, but genomic SMAD3 binding patterns are highly similar in the BTIC-promoting and BTIC-suppressing contexts. Our data show cell-type-specific patterns of DNA and histone modifications provide a modulatory layer by determining accessibility of genes to regulation by TGF-beta/SMAD3. LBH, one such context-specific target gene, is regulated according to its DNA methylation status and is crucial for TGF-beta-dependent promotion of BTICs. Overall, these results reveal that the epigenome plays a central and previously overlooked role in shaping the context-specific effects of TGF-beta in cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据